Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Philadelphia Chromosome 1Myeloproliferative Disorders 1Leukemia, Myeloid, Chronic-Phase 1Leukemia 1

Interventions

Cyclophosphamide 254fludarabine phosphate 165Cytarabine 160Methotrexate 128Busulfan 115Filgrastim 111fludarabine 102Peripheral Blood Stem Cell Transplantation 96Rituximab 94Antilymphocyte Serum 83Etoposide 81Cyclosporine 75Tacrolimus 74Mycophenolic Acid 73Whole-Body Irradiation 72Radiotherapy 70Melphalan 66Vincristine 55Dexamethasone 54Granulocyte Colony-Stimulating Factor 50Methylprednisolone 48Azacitidine 44Alemtuzumab 42Imatinib Mesylate 41Clofarabine 41sargramostim 40Idarubicin 36Daunorubicin 36Cord Blood Stem Cell Transplantation 36Thiotepa 34

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Leukemia × olverembatinib × Clear all
NCT05495035 2023-03-02

Study for Safety and Efficacy of Olverembatinib Combined With APG-2575 in Children With Relapsed/Refractory Ph + ALL

Institute of Hematology & Blood Diseases Hospital, China

Phase 1 Unknown
22 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡